This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Fontaine scheme classification for peripheral arterial disease (PAD)

Authoring team

The Fontaine scheme classifies four stages of peripheral arterial disease (1)

  • peripheral arterial disease can be asymptomatic (Fontaine stage I) or symptomatic (Fontaine stages II-IV)

Stage I: asymptomatic

Stage IIa: mild claudication

Stage IIb: moderate to severe claudication

Stage III: ischaemia rest pain

Stage IV: ulceration or gangrene.

  • the most common symptom of peripheral arterial disease is intermittent claudication (Fontaine stage II), which is characterised by pain in the legs or buttocks that occurs with exercise and is relieved with rest
  • two further stages exist: pain in the extremities at rest (ischaemic rest pain, Fontaine stage III) and necrosis and gangrene (Fontaine stage IV)

Reference:

  1. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2018 Mar 1;39(9):763-816.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.